This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

LGD2226

Ligand Pharmaceuticals, Inc.

Drug Names(s): LGD2226

Description: LGD2226 is a selective androgen receptor modulator (SARM). SARMs, a novel class of orally active non-steroidal molecules that target modulation of the androgen receptor, are designed to enhance the beneficial effects of androgen receptor activation while reducing or eliminating the undesired side effects. The use of currently available oral androgens has been limited due to safety concernsrelated to liver toxicity and concerns over increased risks of prostate cancer.

Deal Structure: In June 2001, Ligand entered into a joint research and development alliance with TAP Pharmaceutical Products to focus on the discovery and development of SARMs. The three-year collaboration carries an option to extend by up to two additional one-year terms. TAP Pharmaceuticals is a partnership of Abbott and Takeda.

In September 2001, Ligand announced that TAP Pharmaceutical Products has elected to proceed with development of LGD2226. Ligand will earn a $1.0 million milestone payment from TAP as a result of this decision. Ligand will receive additional milestone and royalty payments if LGD2226 continues through thedevelopment process and receives marketing approval.

In March 2008, Takeda Pharmaceutical and Abbott concluded their TAP Pharmaceutical Products (TAP) joint venture.

Partners: AbbVie Inc. Takeda Pharmaceutical Company Ltd


LGD2226 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug